Introduction {#Sec1}
============

At the end of 2019 in Wuhan, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was defined as the cause of a novel lower respiratory tract infection. On February 11, 2020 World Health Organization (WHO) officially named the disease as Coronavirus Disease 2019 (COVID-19) \[[@CR1], [@CR2]\]. After WHO officially declared the disease a pandemic on March 11, 2020, many reports showed high infection rates among healthcare workers. Working constantly on mucosal surfaces with high viral loads, it became apparent that Otorhinolaryngologists were at higher risk \[[@CR3]\]. Loss of an Otorhinolaryngologist as the first reported physician death stressed the severity of the situation \[[@CR4]\].

First reports from China described the disease as a lower respiratory tract infection. Common symptoms were fever, cough, and shortness of breath. Upper respiratory symptoms such as sore throat or rhinorrhea were uncommon in these first reports. Major limitation of these studies is that they were conducted on hospitalized patients who had worse forms of the disease \[[@CR5]--[@CR10]\]. Following studies from other countries reported higher incidence of upper respiratory symptoms and lately smell loss has become a prominent future of the disease \[[@CR11]--[@CR18]\].

Although cited studies provided valuable information regarding symptomatology of COVID-19, to the best of our knowledge, no study addressed Otorhinolaryngologic manifestations in whole disease spectrum: from mild to critical patients. In that regard, we aimed to survey every patient that tested positive for SARS-CoV-2 ribonucleic acid (RNA) and substantiate prevalence, duration, severity, and days from onset to diagnosis of general and Otorhinolaryngologic symptoms. As Otorhinolaryngologists are more prone to care for patients with milder forms of the disease, we also wanted to assess whether symptoms differed in this subset compared to severe forms \[[@CR19]\].

Methods {#Sec2}
=======

Setting {#Sec3}
-------

This cross-sectional study was conducted at University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital in Istanbul, Turkey after institutional ethics committee approved the research plan (Date: April 22, 2020, Number: 2730). Written informed consents were obtained from all participants. We assessed patients who had SARS-CoV-2 RNA detected by reverse transcription polymerase chain reaction (RT-PCR) in their nasopharyngeal or oropharyngeal swab specimens. A total of 223 patients (113 males, 110 females) were included.

Patient selection and classification {#Sec4}
------------------------------------

During the time interval of the study, all patients with suspicion of COVID-19 were managed according to interim guidelines published by the Ministry of Health of Turkey Study Board. This guide was updated regularly as new information became available. Resident or attending doctors collected nasopharyngeal and oropharyngeal swabs after a short training following actual interim guide. Specimens were tested for the presence of SARS-CoV-2 RNA by Nucleic Acid Amplification Tests (RT-PCR and nucleic acid sequence analysis when necessary) in the General Directorate of Public Health Microbiology Reference Laboratory \[[@CR20]\].

We searched the tertiary care center University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital Database for adult patients (Age \> 18 years) with initial diagnoses of COVID-19 between March 10 and April 21, 2020. We did not include pediatric population in our study, because classification and management of pediatric COVID-19 cases differed significantly in interim guides \[[@CR20], [@CR21]\]. Patients under the age of 18, those who could not be reached, refused to participate in the study or unable to complete to survey due to underlying health conditions were excluded. The flow diagram for patient recruitment and exclusion and clinical distribution of included patients is provided as Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Patient enrollment process and clinical distribution of patients

We classified patients groups according to disease severity as directed by the national interim guidance and World Health Organization (WHO) interim clinical management guidance (Table [1](#Tab1){ref-type="table"}) \[[@CR20], [@CR21]\]. Considering recent studies that suggest Otorhinolaryngologic symptoms were more common in patients with mild and moderate disease; we combined these two groups together as mild--moderate \[[@CR19]\]. Similarly, we grouped patients in critical and severe groups together as critical--severe for comparison.Table 1Disease severity classification criteriaMild diseaseWith symptoms but without signs suggestive of pneumonia,and SpO~2~ \> 93% on room air,and without chest imaging findings suggestive of viral pneumoniaModerate diseaseWith clinical signs of pneumonia but without severe pneumonia (SpO~2~ ≥ 90% on room air, respiratory rate \< 30 breaths/min, without severe respiratory distress)or with chest imaging findings suggestive of viral pneumoniaSevere diseaseWith severe pneumonia (SpO~2~ \< 90% on room air, respiratory rate \> 30 breaths/min, or severe respiratory distress) but not necessitating Intensive CareCritical diseaseNecessitating intensive-care unit referral*SpO*~*2*~ Oxygen saturation

Survey design {#Sec5}
-------------

After reviewing the literature for reported general and Otorhinolaryngologic symptoms of COVID-19, we prepared a questionnaire for the survey (an English translated version of questionnaire used is provided as Online Resource 1). Commonly reported general symptoms were determined as fever, cough, myalgia/arthralgia, dyspnea, fatigue, and headache. Relevant Otorhinolaryngologic symptoms were found as smell loss, taste loss, sore throat, frontal type headache, rhinorrhea, and nasal congestion \[[@CR5]--[@CR8]\]. There were not yet reports of earache, loss of hearing, facial paralysis, or dizziness during the survey design. We included these symptoms, because they can accompany other well-studied viral diseases \[[@CR22]--[@CR24]\].

Patient interviews {#Sec6}
------------------

Each patient was contacted by the authors: in person if patient was still hospitalized, by phone otherwise. All patients signed the informed consents forms. If patient was discharged during the interview, consents forms were filled online. Author conducting the interview filled the survey form, patients were not asked to fill it by themselves.

Surveying authors first asked the patients to describe their complaints, and then explained each symptom in detail to reduce confusions in context. If the patient had the symptom for longer than 2 months before the hospital referral, it was judged unrelated to COVID-19. Symptom severity was assessed using the Visual Analogue Scale (VAS); a subjective scale of 0--10, with 0 denoting "no symptoms" and 10 "severe symptoms" by asking the patients to consider the time symptoms were the worst to score severity. They were also asked about the onset time of the symptoms to assess symptom duration and time from onset to diagnosis.

Patients who had comorbidities such as Chronic Obstructive Pulmonary Disease (COPD), asthma, or heart failure that could cause symptoms to be chronically present were asked about aggravation rather than presence of such symptoms. During the interviews, it was also made sure that Otorhinolaryngologic symptoms were of new onset and were not explained by any other underlying disease. If patients had ongoing symptoms during the interview, they were contacted via a phone call 1 month later for reassessment. If they still had disease-related complaints at that time, these symptoms were blinded for duration analysis and reported separately.

Of note is that we used the symptom definition as a distress perceived by the patient. We did not report objective variables related to symptoms such as measured body temperature. In that context, presence of fever means: feelings of chills, body temperature changes, or self-measured body temperatures above 38.3 ℃ \[[@CR25], [@CR26]\].

Statistical analysis {#Sec7}
--------------------

All statistical analyses were conducted by SPSS (Version 22.0, Chicago, IL, USA). Continuous variables were expressed as means and standard deviation when normality criteria were met, otherwise as median and ranges. Categorial variables were reported as numbers and percentages. Chi-square test was used to compare categorical variables with Fisher's exact test as needed. Mann--Whitney *U* test was used to compare continuous variables, Statistical significance level was taken as *p *\< 0.05 (two-sided).

When charting boxplots for duration and symptom onset to diagnosis interval; missing symptoms were excluded variable by variable rather than listwise to increase visualization of data.

Results {#Sec8}
=======

Between March 10 and April 21, 2020, 1203 adult patients were tested with suspicion of COVID-19 in our institution. 531 patients had positive tests for SARS-CoV-2 RNA. Of those, 223 patients who met inclusion criteria were enrolled in the study. When we assessed study population for symptomatic distribution, we found that 13 did not have any symptoms (5.8%), 9 (4%) had only Otorhinolaryngologic symptoms, 65 (29.1%) had only general symptoms, and 136 (61.5%) had both general and Otorhinolaryngologic symptoms. Thirteen asymptomatic patients had positive Computed Tomography (CT) scan findings, so they were grouped in the moderate-disease group.

Patients in mild--moderate-disease group were younger, less likely to have positive lung CT scan findings, and less likely to be hospitalized (*p *\< 0.001, *p *= 0.007 and *p *\< 0.001 respectively). Percentage of males was similar between groups. Median days from first symptom onset to hospitalization did not differ (Table [2](#Tab2){ref-type="table"}). Hypertension and diabetes mellitus were more common in severe-critical group (*p *\< 0.001 and *p *= 0.042, respectively). The presence of other comorbidities were similar (Table [3](#Tab3){ref-type="table"}).Table 2Patient characteristics, hospitalization status, CT findings, and days from first symptom onset to diagnosis by disease severityAll patients\
(*N* = 223)Mild--moderate disease\
(*N* = 178)Severe--critical disease\
(*N* = 45)*p* valueMedian or *n*IQR or %Median or *n*IQR or %Median or *n*IQR or %Age5136--624833--596252--71.50 \< 0.001Sex (male)11350.7%8849.4%2555.6%0.463Hospitalization status16272.6%11765.7%45100% \< 0.001CT findings compatible with COVID-1918285%13881.7%4497.8%0.007Days from first symptom onset to diagnosis30--730--731--6.50.422*N* patient number in group, *n* patient number with the trait, *IQR* interquartile range*P* value for mild disease group vs. severe disease groupTable 3Patient comorbidities by disease severityAll patients\
(*N* = 223)Mild--moderate disease\
(*N* = 178)Severe--critical disease\
(*N* = 45)*p* value*n*%*n*%*n*%Hypertension7433.24927.52555.6 \< 0.001Diabetes mellitus4118.42815.71328.90.042Chronic lung disease188.1126.7613.30.147Coronary artery disease177.6137.348.90.754Renal disease125.473.9511.10.069Previous nasal surgery9484.512.20.691Autoimmune disease73.152.824.40.631Chronic rhinosinusitis73.112.263.41Neurologic disease52.242.212.21Cancer41.821.121.80.182Cerebrovascular disease20.610.612.20.364Previous oropharyngeal surgery20.921.1001*N* patient number in group, *n* patient number with the trait*p* value for mild disease group vs. severe disease group

Symptom frequencies, severities, and durations across patients are summarized in Table [4](#Tab4){ref-type="table"}. The most common general symptom was fatigue (71.3%) followed by cough (54.3%), and fever (50.7%). Taste loss, smell loss, and sore throat were common Otorhinolaryngologic symptoms with respective frequencies of 34.5%, 31.8%, and 26%. Only 5 patients reported dizziness (2.2%), 2 loss of hearing (0.9%), and none facial paralysis (0%). Highest general symptom severity was for fatigue with a median VAS score of 8. Highest Otorhinolaryngologic symptom severities were for smell loss and taste loss with median VAS scores of 8. Other median severity VAS scores ranged between 4 and 7.Table 4Patient symptom frequencies, severities, and durationsAll patients\
(*N* = 223)Mild--moderate disease\
(*N* = 178)Severe--critical disease\
(*N* = 45)*p* valueMedian or *n*IQR or %Median or *n*IQR or %Median or *n*IQR or %General symptoms Fatigue  Frequency15971.3%12168%3884.4%0.029  Severity (1--10)85--1075--987--100.042  Duration (Days)106--1596--12.5138.5--22.5 \< 0.001 Cough  Frequency12154.3%9151.1%3066.7%0.062  Severity (1--10)54--855--853.75--7.250.032  Duration (days)127--20117--18.5178--300.059 Fever  Frequency11350.7%8346.6%3066.7%0.016  Severity (1--10)65--865--77.55--9.250.009  Duration (days)52.25--9.7542--974--120.008 Myalgia/arthralgia  Frequency11350.7%9151.1%2248.9%0.789  Severity (1--10)75--975--875--100.478  Duration (days)85--1375--1211.57--170.051 Dyspnea  Frequency8437.7%5229.2%3271.1% \< 0.001  Severity (1--10)53.25--854--873--80.215  Duration (days)73--1652--10126--200.005 Headache  Frequency5926.5%4827%1124.4%0.732  Severity (1--10)65--865--884--80.514  Duration (days)63--115.53--10.7574--120.725Otolaryngologic symptoms Taste loss   Frequency7734.5%6536.5%1226.7%0.214   Severity (1--10)85--1085--108.54--100.555   Duration (days)85--1275--11117.25--160.081 Smell loss   Frequency7131.8%6536.5%613.3%0.003   Severity (1--10)85--1085--106.53.75--100.327   Duration (days)86--13.585--111510.75--18.50.013 Sore throat  Frequency5826%4726.4%1124.4%0.789  Severity (1--10)54--64.54--553--70.642  Duration (days)53--10.553--1095--220.072 Nasal congestion  Frequency3716.6%3016.9%715.6%0.834  Severity (1--10)54--754--773--80.481  Duration (days)84--13.584--10.5132--240.235 Dry throat  Frequency3616.1%2715.2%920%0.431  Severity (1--10)54--843--775--80.040  Duration (Days)64--1153--1011.56.75--240.014 Rhinorrhea  Frequency2611.7%2011.2%613.3%0.695  Severity (1--10)4.53--5.2553.25--532--6.250.407  Duration (days)52.75--12.7552.25--9.7514.52.75--33.750.133 Frontal headache  Frequency2410.8%1810.1%613.3%0.533  Severity (1--10)54.25--855--863.75--8.50.759  Duration (days)53.25--1053--10.55.54--10.250.686 Earache  Frequency62.7%42.2%24.4%0.416  Severity (1--10)43--7.2543--7.25N/AN/AN/A  Duration (days)7.52.75--15.2562.25--9.75N/AN/AN/ADizziness/Vertigo Frequency52.2%10.6%48.9%0.001 Severity (1--10)43.5--7.5N/AN/A54--8.25N/A Duration (Days)7.52.75--14.5N/AN/AN/AN/AN/ALoss of hearing Frequency20.9%00%24.4%0.005 Severity (1--10)N/AN/AN/AN/AN/AN/AN/A Duration (Days)N/AN/AN/AN/AN/AN/AN/AFacial paralysis Frequency00%00%00%N/A Severity (1--10)N/AN/AN/AN/AN/AN/AN/A Duration (Days)N/AN/AN/AN/AN/AN/AN/A*N* patient number in group, *n* patient number with the trait, *IQR* interquartile range, *N/A* not applicable*p* value for mild disease group vs. severe disease group

Percentage of patients with fatigue, fever, or dyspnea was significantly higher in the severe-critical group (*p *= 0.029, *p *= 0.016, and *p *\< 0.001, respectively). Smell loss was more common in the mild--moderate-disease group (*p *= 0.003). Four of five patients that reported hearing loss and two patients that reported dizziness were in severe--critical group. Other symptoms were not different between groups. While median severity VAS scores for fatigue, fever, and dry throat were higher in severe---critical group, median was higher for cough in mild--moderate group. Other symptom severities were similar.

Figure [2](#Fig2){ref-type="fig"} illustrates median symptom durations and interquartile ranges of the patients. Cough was the longest lasting symptom with a median of 12 days. Fatigue followed with a median duration of 10 days. Fatigue, fever, dyspnea, and dry throat lasted longer in severe-critical group (*p *\< 0.001, *p *= 0.008, *p *= 0.005 and *p *= 0.014, respectively). Median duration for smell loss was longer in mild-moderate group (*p *= 0.013). Other symptom durations were similar between groups (Table [4](#Tab4){ref-type="table"}). Ongoing symptoms of ten patients during the 1-month follow-up were not included in the duration analysis (Table [5](#Tab5){ref-type="table"}).Fig. 2Duration distribution of symptoms. Cases were excluded variable by variableTable 5Patient characteristics for ongoing symptoms during 1-month follow-upAgeSexFollow-up day after symptom onsetOngoing symptomsPatient 151Female52Smell loss, taste lossPatient 226Female42Smell loss, taste lossPatient 364Female52Myalgia/arthralgiaPatient 466Female70Smell lossPatient 554Male39Cough, dry throatPatient 636Male37CoughPatient 752Female55DyspneaPatient 840Female45Smell lossPatient 971Female38Smell lossPatient 1031Female45Smell loss, taste loss

We plotted median time interval between the hospital referral day and symptom onset for each symptom in Fig. [3](#Fig3){ref-type="fig"}. Smallest median time interval from symptom onset to diagnosis was for sore throat with 4 days before diagnosis. Median for fatigue, myalgia/arthralgia, and dry throat were 3. Median symptom onset time of dyspnea, smell loss, and taste loss was referral day. For other symptoms, median onset was 1 or 2 days before referral (Table [4](#Tab4){ref-type="table"}).Fig. 3Distribution of time intervals between symptom onset and diagnosis. Cases were excluded variable by variable

Discussion {#Sec9}
==========

COVID-19 presents with many different clinical manifestations, ranging from asymptomatic cases to mild and severe disease---with or without pneumonia. In this study, we surveyed 223 patients with COVID-19 spanning whole disease spectrum. Clinical distribution of our patients is consistent with the largest case series from China that reported 81% mild disease, 14% severe disease, and 5% critical disease \[[@CR27]\]. In that regard, the study succeeded in surveying the whole symptomatic patient population and had a representative sample. Also, by questioning every patient about specific symptoms, we reduced the possibility that patients with more severe forms of the disease might neglect minor symptoms.

Taste loss, smell loss, and sore throat were common Otorhinolaryngologic symptoms found in more than a quarter of patients. Frequencies of general symptoms such as fever, cough, and shortness of breath were much lower than first reports. Not surprisingly fever, dyspnea, and fatigue were significantly more common among severe--critical groups (*p *= 0.016, *p *\< 0.001 and *p *= 0.029 respectively). Actually, numbers were closer to reports from China in this subset, consistent with the idea that the first reports were descriptive of patients with more severe forms of the disease \[[@CR7]\].

By a letter to the editor; Lovato et al. criticized meta-analysis by Sun et al.---which is the largest meta-analysis study on COVID-19 to date---suggesting that true prevalence of sore throat was underestimated \[[@CR5], [@CR28]\]. In a follow-up systemic review, Lovato et al. reported that 12.4% of patients had sore throat. They also stated that most of the studies included in the review only assessed hospitalized patients. This was a limitation of their review \[[@CR9]\]. In our study, sore throat prevalence was 26%. Nasal congestion, dry throat, and rhinorrhea prevalence (16.6%, 16.1%, and 11.7%, respectively) were also higher than previously cited reports. These findings suggest that the previous studies on hospitalized patients might have underestimated such symptoms too.

Most Otorhinolaryngologic symptom prevalence was similar across groups. Only smell loss prevalence was significantly higher in mild--moderate group (*p *= 0.003). These findings support the hypothesis that symptoms might not be mentioned by the patients if not asked directly---especially by severe and critical patients \[[@CR29]\]. Only five patients stated that they had new onset complaints of dizziness and two that of hearing loss. It is possible that these complaints might not actually be related to COVID-19, but coincided with disease onset. Studies on wider populations might clarify this issue.

Our data show that time from symptom onset to diagnosis varies widely as apparent with wide interquartile ranges and error bars in Fig. [3](#Fig3){ref-type="fig"}. In the study population, earliest median symptom onset was for sore throat with 4 days before diagnosis. Fatigue, myalgia/arthralgia, and dry throat had median onset of 3 days before diagnosis. Lower respiratory symptoms fever and cough---which alert clinicians for the presence of pneumonia and COVID-19---had median onsets of 2 days before diagnosis. For dyspnea, median onset time was the day of diagnosis. These findings suggest a possible time frame that patients might have upper respiratory symptoms but no other well-known symptoms of the disease. This is an especially alarming finding as these patients might refer to Otorhinolaryngology clinics, increasing transmission risk.

Another important finding of our study is that symptom duration distribution is also wide (Fig. [2](#Fig2){ref-type="fig"}). Interquartile ranges of symptom durations were wide implying major differences between patients. Longest median duration was of cough with 12 days. After 1-month follow-up, ten patients still had at least one ongoing symptom (Table [5](#Tab5){ref-type="table"}). This suggests that patients with ongoing symptoms after discharge might present to Otorhinolaryngology clinics with extended symptoms such as cough. Aftermath of the first phase of COVID-19 might be especially challenging for Otorhinolaryngology clinics around the globe.

There are many studies addressing smell and taste loss in the literature, each reporting different prevalence \[[@CR19], [@CR30]--[@CR33]\]. A recent meta-analysis reported the prevalence of olfactory dysfunction as 52.73% and gustatory dysfunction as 43.93% \[[@CR15]\]. In our population, smell loss was found in 31.8% and taste loss, in 34.5% of the patients. Median onset time of olfactory and gustatory dysfunctions as diagnosis day is also parallel to the previous findings in the literature \[[@CR16]\]. Six patients still having smell or taste loss after 1 month is concerning: long-term follow-up of these patients was planned. As long-term data are unavailable, it is yet unknown how long symptoms would last or if they would be permanent or not.

Otorhinolaryngology clinics around the world are reorganizing outpatient services to sustain patient care and to minimize the transmission of the disease \[[@CR34], [@CR35]\]. Because many Otorhinolaryngologic examinations are aerosol producing examinations, it is important to determine which patients are at higher risk of disease transmission and take necessary precautions accordingly \[[@CR36], [@CR37]\]. Findings of our study contribute to the literature in that regard: relying solely on fever measurements and questioning of patients only for general symptoms would create a sense of false confidence. This approach risks missing asymptomatic patients or mild-moderate COVID-19 patients who still might be shedding the virus \[[@CR38], [@CR39]\]. Otorhinolaryngologists should not only be alert for general symptoms but also for Otorhinolaryngologic symptoms that could be associated with COVID-19. The absence of more common symptoms should not be interpreted as the absence of the disease.

In our study, there are several limitations to note. Our study was designed to be descriptive only, so multivariate or regression analyzes were not conducted. As Table [2](#Tab2){ref-type="table"} demonstrates, patients in the severe--critical group were older and more of them had comorbidities. That could explain some symptomatologic differences between groups. Such confounding factors should be considered when designing future prospective studies and investigating correlations. We could not include every symptom currently defined in the literature. Gastrointestinal or neurologic manifestations of the disease were not yet widely reported during the design of the survey \[[@CR40], [@CR41]\]. Our study is dependent on self-reports and we did not make any objective measurements, so there is always room for recall bias. Finally, as we only included patients above 18 years old, our results should only be interpreted for this population.

Prospective studies combining patient complaints with objective measurements would be especially valuable to overcome these limitations. Long-term follow-up of COVID-19 patients by Otorhinolaryngologists is also important to better understand disease progression and whether there are permanent sequelae. Our duty as clinicians is to provide continuous and high-quality care for our patients. Having a better understanding of a disease that have such a big impact on patient care will help physicians to reestablish close doctor--patient relationships \[[@CR42]\]. Finally, providing current and correct information to the society is crucial to stop dissemination of false information. People should be aware of the common symptoms and act accordingly, self-isolating when in doubt and seeking medical attention when necessary.

Conclusion {#Sec10}
==========

Otorhinolaryngologic manifestations are not rare symptoms of COVID-19, especially in mild and moderate forms of the disease. The results of this study show that in addition to lower respiratory symptoms, many COVID-19 patients also have Otorhinolaryngologic complaints. Onset of these symptoms might be earlier than that of well-known symptoms such as cough or fever. Mild cases of COVID-19 without clinical pneumonia might represent clinical presentation of the disease in young and healthy individuals. Symptom durations are variable and, in some patients, symptoms such as smell loss might persist months after discharge. Otorhinolaryngologists should be aware of these to provide high-quality care for patients and take necessary precautions to protect themselves.
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